NGS Analysis of Clonality and Minimal Residual Disease in a Patient with Concurrent Richter’s Transformation and CLL/SLL2022-01-08T23:37:03-08:00December 28th, 2021|Read more
Plan for a Successful International Drug Approval with Early Development of the Accompanying CDx2022-01-04T04:43:02-08:00December 8th, 2021|Read more
Machine Learning Algorithms Accelerate Throughput of a Flow – Sequencing Cell Based Assay for an Acute Myeloid Leukemia (AML) Therapeutic Discovery Platform2022-01-30T21:35:17-08:00November 5th, 2021|Read more
Immunoglobulin gene rearrangement in Koreans with multiple myeloma: Clonality assessment and repertoire analysis using next-generation sequencing2022-09-07T22:31:04-07:00June 24th, 2021|Read more
Feasibility of cell-free DNA collection and clonal immunoglobulin sequencing in South African patients with HIV-associated lymphoma2023-01-10T16:48:18-08:00April 28th, 2021|Read more
Invivoscribe To Present At Biotech Showcase™ 2019 In San Francisco2026-10-21T19:22:10-07:00January 3rd, 2019|Read more
US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the USInvivoscribe also Receives National Reimbursement for CDx Assay in Japan2021-02-26T19:11:02-08:00November 29th, 2018|Read more
Invivoscribe Submits LeukoStrat CDx FLT3 Mutation Assay both in the US and Japan to Support Daiichi Sankyo Submissions for Quizartinib2026-10-26T12:38:02-07:00November 27th, 2018|Read more
Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japan2026-10-26T12:15:59-07:00November 19th, 2018|Read more
Invivoscribe® Receives Approval in Japan for its LeukoStrat® CDx FLT3 Mutation Assay to Assess Acute Myeloid Leukemia (AML) Patients Eligible for Treatment with Xospata® (gilteritinib fumarate)2026-10-26T12:32:28-07:00September 27th, 2018|Read more
